Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745396 | 0.91 | CNR1 (0.54) | CNR1HTR2AHTR2CSLC6A4OPRL1 | |
| SCHEMBL3928179 | 0.90 | NOTUM (0.50) | CNR1HTR2AHTR2CSLC6A4CHRNA7 | |
| SCHEMBL3922294 | 0.85 | CNR1 (0.56) | CNR1HTR2AHTR2CSLC6A4CNR2 | |
| SCHEMBL13602551 | 0.85 | HTR2A (0.49) | CNR1HTR2AHTR2CSLC6A4CHRNA7 | |
| SCHEMBL3920985 | 0.84 | CNR1 (0.50) | CNR1HTR2AHTR2CSLC6A4CNR2 | |
| SCHEMBL6464405 | 0.82 | CNR1 (0.71) | CNR1HTR2AHTR2CSLC6A4CNR2 | |
| SCHEMBL13602554 | 0.82 | CNR1 (0.71) | CNR1HTR2AHTR2CSLC6A4CNR2 | |
| SCHEMBL13717141 | 0.82 | CNR1 (0.71) | CNR1HTR2AHTR2CSLC6A4CNR2 | |
| SCHEMBL13717376 | 0.82 | CNR1 (0.71) | CNR1HTR2AHTR2CSLC6A4CNR2 | |
| SCHEMBL13717726 | 0.82 | CNR1 (0.71) | CNR1HTR2AHTR2CSLC6A4CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579369-B2 | CB 1 receptor inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070238754-A1 | Novel CB 1 receptor inverse agonists | MAYWEG ALEXANDER | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238754-A1 | Novel CB 1 receptor inverse agonists | CNR1, CNR2, GPR139 | CNR1 1/4885HTR2A 255/4885HTR2C 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.